Abstract
Although over 90 independent risk variants have been identified for Parkinson’s disease using genome-wide association studies, all studies have been performed in just one population at the time. Here we performed the first large-scale multi-ancestry meta-analysis of Parkinson’s disease with 49,049 cases, 18,785 proxy cases, and 2,458,063 controls including individuals of European, East Asian, Latin American, and African ancestry. In a single joint meta-analysis, we identified 78 independent genome-wide significant loci including 12 potentially novel loci (MTF2, RP11-360P21.2, ADD1, SYBU, IRS2, USP8:RP11-562A8.5, PIGL, FASN, MYLK2, AJ006998.2, Y_RNA, PPP6R2) and finemapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 23 genes near these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations.
Competing Interest Statement
Karl Heilbron and members of the 23andMe Research Team are employed by and hold stock or stock options in 23andMe, Inc. Mike A. Nalls's participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc. Alastair J Noyce. reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Roche, Biogen, UCB, Bial, Charco Neurotech, uMedeor, Alchemab, and Britannia, outside the submitted work.
Funding Statement
Mike A. Nall's research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000535, as well as the National Institute of Neurological Disorders and Stroke (NINDS), and participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. Ignacio Mata's research is supported by grants from the National Institute of Neurological Disorders and Stroke under (R01NS112499), the Parkinson's Foundation (Stanley Fahn Junior Faculty Award and an International Research Grants Program award), the Michael J Fox Foundation, Aligning Science Across Parkinson's Global Parkinson's Genetic Project (ASAP-GP2) and the American Parkinson's Disease Association. Eng-King Tan is supported by a grant from the National Medical Research Council Singapore, Open Fund Large Collaborative Grant (MOH-OFLCG-000207). J.N.F. is supported by the Singapore National Research Foundation Fellowship (NRF-NRFF2016-03) and the National Medical Research Council Singapore, Open Fund Individual Research Grant (MOH-000559). Alastair J. Noyce reports grants from Parkinson's UK, Barts Charity, Cure Parkinson's, NIHR, Innovate UK, Virginia Keiley benefaction, Alchemab, Aligning Science Across Parkinson's Global Parkinson's Genetics Program (ASAP-GP2) and Michael J Fox Foundation. This research was funded by Aligning Science Across Parkinson's through the Michael J. Fox Foundation for Parkinson's Research (MJFF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The authors applied for and were granted access to full summary statistics from 23andMe and genetic data from UK Biobank (application number 33601).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The analysis pipeline code is available on GP2 github: https://github.com/GP2code/GP2-WorkingGroups/tree/main/CD-DAWG-Complex-Data-Analysis/PROJECTS/GP2-Multiancestry-PD GWAS summary statistics for 23andMe datasets (post-Chang and data included in Chang et al. 2017 and Nalls et al. 2014) will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit research.23andme.com/collaborate/#publication for more information and to apply to access the data. An immediately accessible version of the summary statistics is available here https://drive.google.com/file/d/1TmDZNFgyQvsOZ0xu-aZmBpVCpeUUa0UX/ excluding Nalls et al. 2014, 23andMe post-Chang et al. 2017 and Web-Based Study of Parkinson's Disease (PDWBS) but including all analyzed SNPs. After applying with 23andMe, the full summary statistics including all analyzed SNPs and samples in this GWAS meta-analysis will be accessible to the approved researcher(s).
https://drive.google.com/file/d/1TmDZNFgyQvsOZ0xu-aZmBpVCpeUUa0UX/
